Clinical Efficacy of Recombinant Activated Factor VII in Management of Postpartum Hemorrhage

Soo Hyeon Moon; Seung Chul Kim; Jong Kil Joo; Dong Soo Suh; Dong Hyung Lee

doi:10.7469/CSD.2013.24.1.29

Journal List > Korean J Perinatol > v.24(1) > 1013693

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Moon, Kim, Joo, Suh, and Lee: Clinical Efficacy of Recombinant Activated Factor VII in Management of Postpartum Hemorrhage

Original Article

Korean J Perinatol 2013;24(1):29-36.

Published online: 19 February 2013

DOI: https://doi.org/10.7469/CSD.2013.24.1.29

Clinical Efficacy of Recombinant Activated Factor VII in Management of Postpartum Hemorrhage

Soo Hyeon Moon, M.D., Seung Chul Kim, M.D., Ph.D.^∗,, Jong Kil Joo, M.D., Ph.D., Dong Soo Suh, M.D., Ph.D., Dong Hyung Lee, M.D., Ph.D.

Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Korea

주관책임자 : 김승철, 602-739 부산시 서구 구덕로 305 부산대학교 의학전문대학원 산부인과학교실 전화 : 051)240-7282, 전송 : 051)248-2384 E-mail : ksch0127@naver.com

^∗ ∗본 연구는 2011년도 부산대학교병원 임상연구비 지원으로 이루 어졌음.

Received 11 January 2013 Revised 18 March 2013 Accepted 22 March 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose :

This study was aimed to investigate the clinical efficacy of recombinant activated factor VII (rFVIIa) for patients with intractable postpartum hemorrhage.

Methods :

This was a retrospective study of ten patients who were treated with rFVIIa from July 2010 to February 2012 in one tertiary center. To evaluate each case, we used a standardized case record form. The primary outcome measures were response of rFVIIa, reduction of blood product requirement, changes of coagulation parameter. The response of rFVIIa was categorized to three groups: “complete responder”, “partial responder”, “poor responder”.

Results :

After the administration of rFVIIa, effect for bleeding was completely responded in 4 patients, partially responded in 6 patients, and poorly responded in none. A certain amount of reduction in blood product requirements was noted following rFVIIa administration, although no significant differences were observed statistically between before and after rFVIIa administration except RBC (P<0.01). Fibrinogen and INR were significantly reduced in all case types, but other coagulation parameters were not (P<0.01).

Conclusion :

The present results suggest that rFVIIa is a beneficial therapeutic option that could reduce blood loss and contribute to reduction of maternal morbidities and mortalities in patients with massive postpartum hemorrhage.

Go to :

Keywords: Clinical efficacy, Postpartum hemorrhage, Recombinant activated factor VII

REFERENCES

1). Lusher JM. Recombinant factor VIIa (Novoseven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis. 1996. 26(Suppl 1):124–30.

2). Lau P., Ong V., Tan WT., Koh PL., Hartman M. Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding. Transfus Med Hemother. 2012. 39:139–50.

3). Monroe DM., Hoffman M., Oliver JA., Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997. 99:542–7.

4). Hoffman M., Monroe DM., Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998. 9(Suppl 1):S61–5.

5). Mittal S., Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol. 2006. 133:355–63.

6). Kenet G., Walden R., Eldad A., Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999. 354:1879.

7). Mayer SA., Brun NC., Begtrup K., Broderick J., Davis S., Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005. 352:777–85.

8). Friederich PW., Henny CP., Messelink EJ., Geerdink MG., Keller T., Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a doubleblind placebo-controlled randomised trial. Lancet. 2003. 361:201–5.

9). Lodge JP., Jonas S., Oussoultzoglou E., Malago M., Jayr C., Cherqui D, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005. 102:269–75.

10). Singi SR., Fernandez E., Pandya ST., Badrinath HR. Recombinant factor VIIa: use in fatal post partum hemorrhageIndian experience case series and review of literature. Indian J Hematol Blood Transfus. 2009. 25:1–5.

11). Moscardo F., Perez F., de la Rubia J., Balerdi B., Lorenzo JI., Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Hematol. 2001. 114:174–6.

12). Haynes J., Laffan M., Plaat F. Use of recombinant activated factor VII in massive obstetric hemorrhage. Int J Obstet Anesth. 2007. 16:40–9.

13). Alfirevic Z., Elbourne D., Pavord S., Bolte A., Van Geijn H., Mercier F, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol. 2007. 110:1270–8.

14). Ahonen J., Jokela R. Recombinant factor VIIa for life threatening post-partum hemorrhage. Br J Anaesth. 2005. 94:592–5.

15). Hossain N., Shansi T., Haider S., Soomro N., Khan NH., Memon GU, et al. Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand. 2007. 86:1200–6.

16). Ahonen J., Jokela R., Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum hemorrhage. Acta Anaesthesiol Scand. 2007. 51:929–36.

17). Barillari G., Frigo MG., Casarotto M., Farnia A., Masse B., Wetzl R, et al. Use of recombinant activated factor VII in severe postpartum hemorrhage: data from the Italian Registry: a multicentric observational retrospective study. Thromb Res. 2009. 124:e41–7.

18). Franchini M., Lippi G., Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG. 2007. 114:8–15.

19). McMorrow RC., Ryan SM., Blunnie WP., Bowen M., Carton EG., Gardiner J, et al. Use of recombinant factor VIIa in massive post-partum haemorrhage. Eur J Anaesthesiol. 2008. 25:293–8.

20). Phillips LE., McLintock C., Pollock W., Gatt S., Popham P., Jankelowitz G, et al. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009. 109:1908–15.

21). Tanchev S., Platikanov V., Karadimov D. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period. Acta Obstet Gynecol Scand. 2005. 84:402–3.

22). Kobayashi T., Nakabayashi M., Yoshioka A., Maeda M., Ikenoue T. Recombinant activated factor VII (rFVIIa/NovoSeven) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan. Int J Hematol. 2012. 95:57–63.

23). Jan JY., Lin SY., Lin CH., Lee CN., Fan SZ., Han YY. Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: experience from a university hospital in Taiwan. J Obstet Gynaecol Res. 2011. 37:901–7.

24). Welsh A., McLintock C., Gatt S., Somerset D., Popham P., Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008. 48:12–6.

25). Klitgaard T., Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol. 2008. 65:3–11.

26). Kessler CM. Antidotes to haemorrhage: recombinant factor VIIa. Best Pract Res Clin Haematol. 2004. 17:183–97.

Go to :

Fig. 1

Comparison of requirement of RBC, FFP and PLT concentrates before (A) and after (B) administration of rFVIIa.

undefined

Fig. 2

Comparison of aPTT, fibrinogen, INR and platelets level before (A) and after (B) administration of rFVIIa.

undefined

Table 1.

Patient Characteristics and Obstetric Data in Parturients Receiving rFVIIa

No	Age (years)	Parity	Gestational age (weeks)	Mode of delivery	Causes of bleeding	Interventions prior to infusion of rFVIIa
1	33	1	37	CD	Uterine atony	Hysterectomy
2	21	1	39	VD	Uterine atony	Right UAE
3	37	1	38	CD	Uterine vessel injury	Both UAE
4	33	1	39	VD	Cervical/vaginal laceration	Right UAE
5	41	1	29	CD	Uterine atony, preeclampsia	Intraperitoneal, intrauterine hematoma evacuation
6	27	1	40	VD	Uterine vessel injury	Bilateral internal iliac artery embolization
7	43	1	35	CD	Placenta previa totalis	Hysterectomy
8	30	1	39	VD	Uterine atony	Both UAE
9	39	1	37	VD	Uterine atony	Both UAE
10	36	2	40	VD	Placenta accreta	Hysterectomy, gauze packing

Abbreviations: CD, cesarean delivery; VD, vaginal delivery; UAE, uterine artery embolization

Table 2.

Comparison of Blood Products Requirement before and within 24 Hours after Initial rFVIIa Administration

No	Dosage of rFVIIa	Response	RBC (U)∗		FFP (U)		PLT concentrates (U)
No	Dosage of rFVIIa	Response	Before	After	Before	After	Before	After
1	80 μg/kg	Complete	30	0	22	6	14	10
2	80 μg/kg	Partial	6	0	6	3	0	0
3	80 μg/kg	Complete	25	3	21	6	28	8
4	80 μg/kg	Partial	5	7	5	9	0	0
5	80 μg/kg	Complete	14	5	8	7	9	6
6	85 μg/kg	Partial	13	10	3	15	16	16
7	85 μg/kg	Partial	47	12	32	3	24	8
8	85 μg/kg	Partial	15	10	17	8	39	23
9	85 μg/kg	Partial	24	12	25	15	16	32
10	85 μg/kg	Complete	23	2	25	4	18	0
	Median (range)		19 (5-47)	6 (0-12)	19 (3-25)	6.5 (3-15)	16 (0-39)	8 (0-32)

Abbreviations: RBC, red blood cells; FFP, frech frozen plasma; U, unit P values are calculated using Wilcoxon signed rank sum test (∗<0.01 was considered statistically significant)

Table 3.

Comparison of aPTT/INR, Fibrinogen and Platelet Level before and after Initial rFVIIa Administration

No	Dosage of rFVIIa	Response	aPTT (seconds)		INR∗		Fibrinogen∗ (mg/dL)		Platelet (x10³/U)
No	Dosage of rFVIIa	Response	Before	After	Before	After	Before	After	Before	After
1	80 μg/kg	Complete	131.4	78.0	10.0	1.79	55.6	50.0	71	101
2	80 μg/kg	Partial	180.0	44.9	1.93	0.95	79.7	64.0	70	53
3	80 μg/kg	Complete	54.9	42.7	1.31	0.82	120.0	110.0	36	58
4	80 μg/kg	Partial	60.8	38.8	1.35	1.26	94.0	80.0	123	82
5	80 μg/kg	Complete	61.8	52.8	1.62	1.14	102.0	100.0	85	69
6	85 μg/kg	Partial	67.4	51.7	1.50	1.39	107.2	90.0	95	138
7	85 μg/kg	Partial	111.6	50.9	1.41	1.20	65.0	60.0	91	93
8	85 μg/kg	Partial	69.0	180.0	1.74	1.29	54.0	50.0	79	104
9	85 μg/kg	Partial	180.0	180.0	3.50	3.00	150.0	140.0	100	61
10	85 μg/kg	Complete	60.0	33.4	1.32	1.01	160.0	138.0	150	85
	Median (range)		68.2 (54.9-180.0)	51.3 (33.4-180.0)	1.56 (1.31-10.0)	1.23 (0.82-3.0)	98.0 (54.0-160.0)	85.0 (50.0-140.0)	86.0 (36.0-150.0)	83.5 (53.0-138.0)

Abbreviations: U, unit; aPTT, activated partial thromboplastin time; INR, International Normalized Ratio P values are calculated using Wilcoxon signed rank sum test (∗<0.01 was considered statistically significant)

TOOLS

Similar articles